| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.3 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.3 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |